Company Description
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types.
Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications.
It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 10, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 339 |
| CEO | Dr. Scott Koenig M.D., Ph.D. |
Contact Details
Address: 9704 Medical Center Drive Rockville, Maryland 20850 United States | |
| Phone | 301-251-5172 |
| Website | macrogenics.com |
Stock Details
| Ticker Symbol | MGNX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001125345 |
| CUSIP Number | 556099109 |
| ISIN Number | US5560991094 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Scott Koenig M.D., Ph.D. | President, Chief Executive Officer and Director |
| James Karrels | Senior Vice President, Chief Financial Officer and Corporate Secretary |
| Dr. Stephen L. Eck M.D., Ph.D. | Senior Vice President of Clinical Development and Chief Medical Officer |
| Eric Blasius Risser | Chief Operating Officer |
| Dr. Thomas M. Spitznagel Ph.D. | Senior Vice President of Technical Operations |
| Dr. Ezio Bonvini M.D. | Senior Vice President of Research and Chief Scientific Officer |
| Jeffrey Stuart Peters | Senior Vice President, General Counsel and Corporate Compliance Officer |
| Lynn Cilinski | Vice President, Controller and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2024 | ARS | Filing |
| Apr 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2024 | 144 | Filing |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 10-K | Annual Report |
| Mar 6, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |